- Home
- BMRA vs CVKD Comparison
BMRA vs CVKD Comparison
Compare BMRA & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- CVKD
- Stock Information
- Founded
- BMRA 1971
- CVKD 2022
- Country
- BMRA United States
- CVKD United States
- Employees
- BMRA N/A
- CVKD N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- BMRA Health Care
- CVKD Health Care
- Exchange
- BMRA Nasdaq
- CVKD Nasdaq
- Market Cap
- BMRA 8.1M
- CVKD 29.5M
- IPO Year
- BMRA N/A
- CVKD 2023
- Fundamental
- Price
- BMRA $3.02
- CVKD $12.11
- Analyst Decision
- BMRA
- CVKD Strong Buy
- Analyst Count
- BMRA 0
- CVKD 1
- Target Price
- BMRA N/A
- CVKD $32.00
- AVG Volume (30 Days)
- BMRA 72.7K
- CVKD 35.2K
- Earning Date
- BMRA 08-27-2025
- CVKD 08-06-2025
- Dividend Yield
- BMRA N/A
- CVKD N/A
- EPS Growth
- BMRA N/A
- CVKD N/A
- EPS
- BMRA N/A
- CVKD N/A
- Revenue
- BMRA $5,678,000.00
- CVKD N/A
- Revenue This Year
- BMRA N/A
- CVKD N/A
- Revenue Next Year
- BMRA N/A
- CVKD N/A
- P/E Ratio
- BMRA N/A
- CVKD N/A
- Revenue Growth
- BMRA 5.01
- CVKD N/A
- 52 Week Low
- BMRA $1.93
- CVKD $5.70
- 52 Week High
- BMRA $10.16
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- BMRA 42.21
- CVKD 49.98
- Support Level
- BMRA $2.95
- CVKD $11.00
- Resistance Level
- BMRA $3.78
- CVKD $13.56
- Average True Range (ATR)
- BMRA 0.23
- CVKD 1.15
- MACD
- BMRA -0.00
- CVKD 0.25
- Stochastic Oscillator
- BMRA 20.00
- CVKD 80.97
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.